ARTICLE | Company News
OncoGenex, Teva deal
January 4, 2010 8:00 AM UTC
OncoGenex granted Teva exclusive, worldwide rights to develop and commercialize OGX-011. The second-generation antisense inhibitor of clusterin mRNA is expected to start Phase III testing this year ...